MicroRNA-126 selected with broad-spectrum analysis of microRNAs – a new predictive factor for the effectiveness of immunotherapy or chemoimmunotherapy in advanced NSCLC patients?

MicroRNA-126 selected with broad-spectrum analysis of microRNAs – a new predictive factor for the effectiveness of immunotherapy or chemoimmunotherapy in advanced NSCLC patients?

IntroductionExpression of PD-L1 on cancer cells is the only validated predictive factor for immunotherapy in NSCLC (Non-Small Cell Lung Cancer) patients. However, on this basis, it is difficult to predict the occurrence of resistance to immune checkpoint inhibitors (ICIs). MicroRNAs are widely studi...

Full description

Bibliographic Details
Main Authors: Anna Grenda, Barbara Kuźnar-Kamińska, Ewa Kalinka, Paweł Krawczyk, Marek Sawicki, Agata Filip, Izabela Chmielewska, Małgorzata Frąk, Natalia Krzyżanowska, Janusz Milanowski
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-02-01
Series:Frontiers in Immunology
Subjects:
microRNA
immunotherapy
anti-PD-1
NSCLC
miRNA
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1344858/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2024.1344858/full

Similar Items